Cargando…
Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature
Amyopathic dermatomyositis (ADM) is a rare subtype of dermatomyositis which is often recalcitrant to immune suppressing treatments. Intravenous immunoglobulin (IVIG) has been used in the treatment of refractory dermatomyositis. We present two patients with severe ADM, who were treated with IVIG at 2...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676053/ https://www.ncbi.nlm.nih.gov/pubmed/26668670 http://dx.doi.org/10.2174/1874312901409010077 |
_version_ | 1782405102419574784 |
---|---|
author | Cafardi, John M. Sami, Naveed |
author_facet | Cafardi, John M. Sami, Naveed |
author_sort | Cafardi, John M. |
collection | PubMed |
description | Amyopathic dermatomyositis (ADM) is a rare subtype of dermatomyositis which is often recalcitrant to immune suppressing treatments. Intravenous immunoglobulin (IVIG) has been used in the treatment of refractory dermatomyositis. We present two patients with severe ADM, who were treated with IVIG at 2 g/kg every four weeks. Both patients had a successful response and were able to taper the dosage of prednisone. We present both cases in describing IVIG as a rescue and maintenance steroid-sparing agent in the treatment of severe refractory ADM. We also review the treatment of refractory ADM with IVIg in the English literature. |
format | Online Article Text |
id | pubmed-4676053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-46760532015-12-14 Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature Cafardi, John M. Sami, Naveed Open Rheumatol J Article Amyopathic dermatomyositis (ADM) is a rare subtype of dermatomyositis which is often recalcitrant to immune suppressing treatments. Intravenous immunoglobulin (IVIG) has been used in the treatment of refractory dermatomyositis. We present two patients with severe ADM, who were treated with IVIG at 2 g/kg every four weeks. Both patients had a successful response and were able to taper the dosage of prednisone. We present both cases in describing IVIG as a rescue and maintenance steroid-sparing agent in the treatment of severe refractory ADM. We also review the treatment of refractory ADM with IVIg in the English literature. Bentham Open 2015-11-04 /pmc/articles/PMC4676053/ /pubmed/26668670 http://dx.doi.org/10.2174/1874312901409010077 Text en © Cafardi and Sami ; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Cafardi, John M. Sami, Naveed Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature |
title | Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature |
title_full | Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature |
title_fullStr | Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature |
title_full_unstemmed | Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature |
title_short | Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature |
title_sort | intravenous immune globulin in amyopathic dermatomyositis - report of two cases and review of the literature |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676053/ https://www.ncbi.nlm.nih.gov/pubmed/26668670 http://dx.doi.org/10.2174/1874312901409010077 |
work_keys_str_mv | AT cafardijohnm intravenousimmuneglobulininamyopathicdermatomyositisreportoftwocasesandreviewoftheliterature AT saminaveed intravenousimmuneglobulininamyopathicdermatomyositisreportoftwocasesandreviewoftheliterature |